3-[(tert-butyldimethylsilyl)oxy]-N-ethylaniline | 268233-43-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-[(tert-butyldimethylsilyl)oxy]-N-ethylaniline
• 英文别名: 3-[tert-butyl(dimethyl)silyl]oxy-N-ethylaniline
• CAS: 268233-43-8
• 化学式: C₁₄H₂₅NOSi
• 分子量: 251.444
• InChiKey: IPKQZSIVVGIJKB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  17
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  21.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-[(tert-butyldimethylsilyl)oxy]-N-ethylaniline 在 三乙胺 、 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 32.0h， 生成 N-ethyl-2-fluoro-N-(3-hydroxyphenyl)benzamide
  参考文献：
  名称：

  [EN] ABAD INHIBITOR COMPOUNDS
  [FR] COMPOSÉS INHIBITEURS D'ABAD

  摘要：

  The present invention concerns Amyloid Binding Alcohol Dehydrogenase (ABAD) inhibitors (I) or (II) that interact non- competitively with nicotinamide adenine dinucleotide + H (NADH). Inhibition of ABAD is useful in the treatment or prophylaxis of disease, including Alzheimer's disease (AD) and cancer. Accordingly, the present invention also concerns ABAD inhibitors for use as a medicament, specifically for use in the treatment of Alzheimer's disease and/or cancer.

  公开号：

  WO2023026060A1
• 作为产物：
  描述：

  3-乙基氨基苯酚 、 叔丁基二甲基氯硅烷 在 咪唑 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 以88.99 %的产率得到3-[(tert-butyldimethylsilyl)oxy]-N-ethylaniline
  参考文献：
  名称：

  [EN] ABAD INHIBITOR COMPOUNDS
  [FR] COMPOSÉS INHIBITEURS D'ABAD

  摘要：

  The present invention concerns Amyloid Binding Alcohol Dehydrogenase (ABAD) inhibitors (I) or (II) that interact non- competitively with nicotinamide adenine dinucleotide + H (NADH). Inhibition of ABAD is useful in the treatment or prophylaxis of disease, including Alzheimer's disease (AD) and cancer. Accordingly, the present invention also concerns ABAD inhibitors for use as a medicament, specifically for use in the treatment of Alzheimer's disease and/or cancer.

  公开号：

  WO2023026060A1

文献信息

• Vitamin D analogues
  申请人：Galderma Research & Development S.N.C.

  公开号：US06689922B1

  公开（公告）日：2004-02-10

  The invention concerns novel bi-aromatic compounds having the formula: which are analogs of vitamin D, the process of preparing them, as well as their use in pharmaceutical compositions in human or veterinary medicine, particularly in dermatology, cancer treatment, treatment of auto-immune diseases, and in organ or tissue transplants. Cosmetic compositions and methods of use are also included.

  这项发明涉及具有以下公式的新型双芳香化合物：这些化合物是维生素D的类似物，涉及它们的制备过程，以及它们在人类或兽医药学中的药用组合物中的使用，特别是在皮肤病学、癌症治疗、自身免疫疾病治疗以及器官或组织移植中。还包括化妆品组合物和使用方法。
• [EN] ABAD INHIBITOR COMPOUNDS<br/>[FR] COMPOSÉS INHIBITEURS D'ABAD
  申请人：[en]UNIVERSITY COURT OF THE UNIVERSITY OF ST ANDREWS

  公开号：WO2023026060A1

  公开（公告）日：2023-03-02

  The present invention concerns Amyloid Binding Alcohol Dehydrogenase (ABAD) inhibitors (I) or (II) that interact non- competitively with nicotinamide adenine dinucleotide + H (NADH). Inhibition of ABAD is useful in the treatment or prophylaxis of disease, including Alzheimer's disease (AD) and cancer. Accordingly, the present invention also concerns ABAD inhibitors for use as a medicament, specifically for use in the treatment of Alzheimer's disease and/or cancer.